Call Options

9 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$51.3 - $64.42 $1.05 Million - $1.32 Million
20,500 Added 107.33%
39,600 $2.27 Million
Q2 2024

Aug 14, 2024

BUY
$37.81 - $52.4 $52,934 - $73,360
1,400 Added 7.91%
19,100 $1 Million
Q1 2024

May 15, 2024

SELL
$33.68 - $41.95 $43,784 - $54,535
-1,300 Reduced 6.84%
17,700 $720,000
Q4 2023

Feb 14, 2024

SELL
$33.32 - $42.1 $569,772 - $719,910
-17,100 Reduced 47.37%
19,000 $702,000
Q3 2023

Nov 14, 2023

BUY
$36.46 - $44.03 $185,946 - $224,553
5,100 Added 16.45%
36,100 $1.38 Million
Q2 2023

Aug 14, 2023

BUY
$30.28 - $38.74 $181,680 - $232,440
6,000 Added 24.0%
31,000 $1.12 Million
Q1 2023

May 15, 2023

SELL
$32.86 - $55.7 $555,334 - $941,330
-16,900 Reduced 40.33%
25,000 $954,000
Q4 2022

Feb 14, 2023

BUY
$40.06 - $59.44 $368,552 - $546,848
9,200 Added 28.13%
41,900 $2.38 Million
Q3 2022

Nov 14, 2022

SELL
$38.53 - $51.78 $1.19 Million - $1.6 Million
-30,900 Reduced 48.58%
32,700 $1.29 Million

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $6.62B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.